Please login to the form below

Not currently logged in
Email:
Password:

Shionogi-ViiV

This page shows the latest Shionogi-ViiV news and features for those working in and with pharma, biotech and healthcare.

GSK shelves ViiV sale as it lays out growth strategy

GSK shelves ViiV sale as it lays out growth strategy

Shares in the company traded up in the decision to hang onto ViiV - partnered with Pfizer and Shionogi but with GSK owning an 80% stake - as well as bullish statements from ... underlying performance at ViiV, GSK has come to the sensible decision to

Latest news

  • Developing your patient-centric strategy Developing your patient-centric strategy

    the GSK, Pfizer and Shionogi joint venture - and Gilead, two companies with a strong or, in ViiV's case exclusive, presence in HIV/AIDS products. ... ViiV's CEO Dr Dominique Limet said then: “ We have to get closer to those people who live with the

  • ViiV wins European approval for Tivicay ViiV wins European approval for Tivicay

    ViiV wins European approval for Tivicay. HIV treatment licensed in combination with other anti-retroviral drugs. ... ViiV was formed as an HIV-focused joint venture between GlaxoSmithKline and Pfizer in 2009 and welcomed  Shionogi - the originator of

  • FDA clears Isentress formulation for infants with HIV FDA clears Isentress formulation for infants with HIV

    Tivicay (dolutegravir) – a fellow integrase inhibitor developed by the GlaxoSmithKline/Pfizer/Shionogi joint venture ViiV Healthcare – was approved in the US in combination with other antiretroviral agents to treat patients aged

  • ViiV's Tivicay for HIV on course for EU approval ViiV's Tivicay for HIV on course for EU approval

    ViiV's Tivicay for HIV on course for EU approval. More positive news for GSK, Pfizer and Shionogi joint venture. ... It is the first product launched by ViiV, which is an HIV-focused joint venture between GlaxoSmithKline, Pfizer and Shionogi.

  • China weighs heavy on GSK figures in Q3 China weighs heavy on GSK figures in Q3

    There were also launches for melanoma drugs Tafinlar (dabrafenib) and Mekinist (trametinib), Tivicay (dolutegravir) for HIV via GSK's ViiV joint venture with Pfizer and Shionogi, and new COPD therapy Breo

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    The first is the revised deal between ViiV Healthcare (the speciality HIV company formed by GSK and Pfizer in 2009) and Shionogi. ... Under the new agreement, ViiV Healthcare will acquire the exclusive global rights to the assets in the Shionogi-ViiV

  • Shionogi: an expanding commercial focus Shionogi: an expanding commercial focus

    The candidate the company is most excited about is the nce-daily HIV integrase inhibitor dolutegravir, which Shionogi is co-developing with the Pfizer and GlaxoSmithKline's ViiV Healthcare venture. ... Establishes Shionogi-GlaxoSmithKline joint venture

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Developing your patient-centric strategy

    Healthcare - the GSK, Pfizer and Shionogi joint venture - and Gilead, two companies with a strong or, in ViiV’ s case exclusive, presence in HIV/AIDS products. ... Nevertheless, it’ s worth revisiting the announcement of ViiV’ s birth four and a

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics